
FDA-approved Chinese cancer drug to be sold in US under Zegfrovy brand
The story in brief
AstraZeneca has acquired worldwide rights to commercialise Zegfrovy, a lung cancer drug approved in China in 2023 and by the FDA in July 2025. At least 30 Americans, including Max Doppelt, flew to China to access the drug, with Doppelt’s mother still alive and working after three years of treatment.